.png)
San Diego, DATE, 2018 (BUSINESS WIRE) - Scientist.com, the world's leading marketplace for outsourced scientific services, and Allele Biotechnology & Pharmaceuticals Inc., a leading San Diego-based preclinical-stage biopharmaceutical company, have partnered to develop nanoantibodies for therapeutic applications. Experts selected through Scientist.com’s Genius Consulting NetworkTM will assist Allele in applying its proprietary nanoantibody technology to multiple therapeutic areas.
“Allele Biotech has developed novel cutting-edge nanoantibody technologies with considerable therapeutic potential,” stated Kevin Lustig, PhD, Scientist.com’s CEO and Founder. “This partnership enables Allele to focus on exploring therapeutic applications of its proprietary nanoantibody candidates.”
Allele’s nanoantibodies are recombinant, fully humanized, camelid single-domain heavy-chain only (VHH) antibodies that can be linked together to produce multivalent new molecular entities. With their unique structure, small size, and ability to bind multiple targets with one construct, nanoantibodies are ideal for generating novel biologics.
“Scientist.com makes it easy for us to connect with industry-leading experts in drug discovery and development,” stated Dr. Jiwu Wang, CEO of Allele Biotech. “We use the marketplace to find the experts and services we need for our internal R&D programs.”
Scientist.com’s recently launched Genius Consulting Network offers access to world-class experts in pre-clinical and clinical research, IND-enabling programs, translational research, CMC services, NDA submission and commercial assessments, among other areas.
About Allele Biotechnology & Pharmaceuticals Inc.
“Allele Biotechnology and Pharmaceuticals, Inc. is a private, San Diego-based company that builds unique platforms based on cutting-edge science to generate disruptive therapies. Allele uses proprietary technology for discovery and production of single domain nanoantibodies for highly valuable and diversified targets through its own powerful workflow established over the past 9 years. To date, Allele has generated recombinant nanoantibodies against over 20 different biomedically important antigens in the fields of inflammatory diseases, cancer, and cardiovascular diseases, among others. Allele is moving a number of programs supported by in vivo data through pre-clinical stages.”
.webp)
Scientist.com
Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.
We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.
Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.